Merck

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Merck 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About MRK

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. 

CEO
Robert M. Davis
CEORobert M. Davis
Employees
75,000
Employees75,000
Headquarters
Rahway, New Jersey
HeadquartersRahway, New Jersey
Founded
1891
Founded1891
Employees
75,000
Employees75,000

MRK Key Statistics

Market cap
317.50B
Market cap317.50B
Price-Earnings ratio
35.96
Price-Earnings ratio35.96
Dividend yield
2.63%
Dividend yield2.63%
Average volume
8.57M
Average volume8.57M
High today
$131.07
High today$131.07
Low today
$127.56
Low today$127.56
Open price
$129.41
Open price$129.41
Volume
9.50M
Volume9.50M
52 Week high
$135.05
52 Week high$135.05
52 Week low
$77.58
52 Week low$77.58

Stock Snapshot

Merck(MRK) stock is priced at $128.33, giving the company a market capitalization of 317.5B. It carries a P/E multiple of 35.96 and pays a dividend yield of 2.63%.

During the trading session on 2026-08-05, Merck(MRK) shares reached a daily high of $131.07 and a low of $127.56. At a current price of $128.33, the stock is +0.6% higher than the low and still -2.1% under the high.

Trading activity shows a volume of 9.5M, compared to an average daily volume of 8.57M.

The stock's 52-week range extends from a low of $77.58 to a high of $135.05.

The stock's 52-week range extends from a low of $77.58 to a high of $135.05.

MRK News

TipRanks 6h
Merck announces Health Canada approval of KEYTRUDA for adults with MIBC

Merck (MRK) announced that KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with enfortumab vedotin, an antibody-drug conjugate, is approved by Health Canada...

Simply Wall St 9h
Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope

The race to treat obesity and metabolic disease is reshaping expectations across large pharmaceutical stocks, and Eli Lilly is front and center after its Q2 ear...

Eli Lilly Stock Rally Puts Obesity Drug Shares Under The Microscope
CNBC 22h
Merck CEO says new pipeline is built to offset Keytruda's eventual patent expiration - CNBC

...

Merck CEO says new pipeline is built to offset Keytruda's eventual patent expiration - CNBC

Analyst ratings

63%

of 30 ratings
Buy
63.3%
Hold
30%
Sell
6.7%

More MRK News

Benzinga 1d
Why Merck Just Slashed Its Profit Outlook By Nearly 50%

Merck Revenue Tops Estimates Despite Acquisition Charges The company reported an adjusted loss of 13 cents per share, narrower than analysts’ expected loss of...

Why Merck Just Slashed Its Profit Outlook By Nearly 50%
TipRanks 1d
Merck Buy Rating Reaffirmed as Analyst Highlights Emerging HIV Franchise and Maintains $137 Price Target

Goldman Sachs analyst Asad Haider maintained a Buy rating on Merck & Company yesterday and set a price target of $137.00. Claim 55% Off TipRanks Unlock powerful...

Nasdaq 1d
Merck & Co Q2 26 Earnings Conference Call At 9:00 AM ET

(RTTNews) - Merck & Co Inc. (MRK) will host a conference call at 9:00 AM ET on August 4, 2026, to discuss Q2 26 earnings results. o access the live webcast, lo...

Merck & Co Q2 26 Earnings Conference Call At 9:00 AM ET
Nasdaq 1d
Merck & Co. Posts Loss In Q2; Raises, Narrows FY Sales Guidance Range

(RTTNews) - Merck & Co., Inc. (MRK) reported a GAAP net loss of $1.3 billion in the second quarter of 2026, compared to net income of $4.4 billion in the second...

Merck & Co. Posts Loss In Q2; Raises, Narrows FY Sales Guidance Range
Seeking Alpha 1d
Merck lifts sales forecast as newer drugs gain momentum

Merck (MRK) reported second-quarter results that topped Wall Street expectations, driven by continued strength in its blockbuster cancer drug Keytruda, as well...

Merck lifts sales forecast as newer drugs gain momentum
TipRanks 1d
Merck cuts FY26 adjusted EPS view to $2.66-$2.76 from $5.04-$5.16

FY26 consensus $2.76. Raises FY26 revenue view to $66.3B-$67.3B from $65.8B-$67B, consensus $66.89B. Outlook includes charges of $2.43 per share for the acquisi...

Investor's Business Daily 1d
The Merck Product That Absolutely Demolished Wall Street's Forecasts

Technology The Merck Product That Absolutely Demolished Wall Street's Forecasts Licensing Merck's (MRK) new injectable version of Keytruda walloped sales expect...

The Merck Product That Absolutely Demolished Wall Street's Forecasts

People also own

Based on the portfolios of people who own MRK. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.